Physician profile
Christopher P Farrell
NPI 1619127610
$3,213.93
in general payments reported to CMS, 2019-2025
23 companies · $601 in 2025
The $601 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $252 · 2021: $99.82 · 2022: $667 · 2023: $477 · 2024: $315 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,680.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.36 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.20 | 2019-2022 | |
| Pfizer INC. | $153.13 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $152.40 | 2019-2023 | Ocaliva |
| Janssen Biotech, INC. | $131.86 | 2019-2025 | Tremfya, Stelara |
| Abiomed | $107.06 | 2024 | Impella |
| Celgene Corporation | $87.15 | 2022-2023 | Zeposia |
| Novo Nordisk INC | $60.14 | 2025 | Wegovy |
| Celltrion USA INC. | $38.76 | 2025 | Vegzelma |
| Genzyme Corporation | $35.42 | 2025 | |
| Qol Medical, LLC | $35.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.97 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $29.11 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $24.65 | 2024 | Iqirvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.62 | 2025 | Omvoh |
| Shionogi INC | $21.98 | 2019 | |
| Merck Sharp & Dohme LLC | $19.03 | 2022 | |
| Ucb, INC. | $17.85 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.57 | 2022 | |
| Alfasigma USA, INC. | $14.97 | 2020 | |
| Gilead Sciences, INC. | $14.24 | 2023 | |
| Shire North American Group INC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.